BAYER HLTHCARE FDA Approval NDA 021473

NDA 021473

BAYER HLTHCARE

FDA Drug Application

Application #021473

Documents

Letter2002-12-13
Letter2004-07-21
Letter2007-07-05
Letter2008-01-23
Letter2008-10-07
Letter2009-05-07
Letter2011-11-21
Letter2011-08-08
Letter2013-01-31
Letter2016-07-26
Label2002-12-16
Label2004-07-21
Label2008-10-09
Label2009-05-11
Label2011-11-16
Label2013-08-15
Label2016-07-26
Review2007-07-09
Review2007-07-09
Review2007-07-09
Review2007-07-09
Other2016-02-03
Letter2004-07-21
Letter2004-07-21
Letter2005-05-20
Letter2005-11-18
Letter2009-06-30
Letter2011-03-02
Letter2011-06-15
Letter2011-10-20
Letter2013-08-16
Letter2015-02-02
Label2004-07-21
Label2004-07-21
Label2005-05-20
Label2005-11-17
Label2007-06-27
Label2008-01-23
Label2011-03-04
Label2011-06-14
Label2011-11-04
Label2013-02-01
Label2015-02-03
Review2003-11-06
Review2007-07-09
Label2017-07-27
Letter2017-07-28
Label2018-10-19
Letter2018-10-23
Letter2019-05-07
Label2019-05-08
Label2020-03-06
Medication Guide2020-03-06
Letter2020-03-09
Letter2020-05-11
Label2020-05-11
Medication Guide2020-05-11
Letter2021-03-31
Label2021-04-01
Medication Guide2021-04-01

Application Sponsors

NDA 021473BAYER HLTHCARE

Marketing Status

Discontinued001
Discontinued002

Application Products

001TABLET, EXTENDED RELEASE;ORAL212.6MG;EQ 287.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**0CIPRO XRCIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE
002TABLET, EXTENDED RELEASE;ORAL425.2MG;EQ 574.9MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**0CIPRO XRCIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2002-12-13STANDARD
LABELING; LabelingSUPPL5AP2004-07-14STANDARD
LABELING; LabelingSUPPL6AP2004-07-14STANDARD
LABELING; LabelingSUPPL7AP2004-07-14STANDARD
LABELING; LabelingSUPPL9AP2005-05-18STANDARD
LABELING; LabelingSUPPL13AP2005-11-09STANDARD
LABELING; LabelingSUPPL16AP2006-06-19STANDARD
LABELING; LabelingSUPPL22AP2007-06-25STANDARD
LABELING; LabelingSUPPL23AP2008-01-18STANDARD
LABELING; LabelingSUPPL24AP2008-10-03STANDARD
LABELING; LabelingSUPPL25AP2009-04-27STANDARD
LABELING; LabelingSUPPL26AP2009-06-24STANDARD
LABELING; LabelingSUPPL27AP2011-11-15STANDARD
LABELING; LabelingSUPPL28AP2011-02-25901 REQUIRED
LABELING; LabelingSUPPL31AP2011-06-10STANDARD
REMS; REMSSUPPL32AP2011-08-03N/A
LABELING; LabelingSUPPL33AP2011-10-18UNKNOWN
LABELING; LabelingSUPPL34AP2013-01-30STANDARD
LABELING; LabelingSUPPL35AP2013-08-14901 REQUIRED
LABELING; LabelingSUPPL36AP2015-01-30STANDARD
LABELING; LabelingSUPPL37AP2016-07-26STANDARD
LABELING; LabelingSUPPL38AP2017-07-26STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
LABELING; LabelingSUPPL39AP2018-10-18STANDARD
LABELING; LabelingSUPPL40AP2019-05-03STANDARD
LABELING; LabelingSUPPL41AP2020-03-05STANDARD
LABELING; LabelingSUPPL42AP2020-05-08STANDARD
LABELING; LabelingSUPPL43AP2021-03-30STANDARD

Submissions Property Types

SUPPL5Null9
SUPPL6Null9
SUPPL25Null7
SUPPL27Null7
SUPPL28Null6
SUPPL31Null7
SUPPL32Null7
SUPPL33Null15
SUPPL34Null6
SUPPL35Null6
SUPPL36Null7
SUPPL37Null7
SUPPL38Null15
SUPPL39Null6
SUPPL40Null6
SUPPL41Null6
SUPPL42Null7
SUPPL43Null15

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21473
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.